BACKGROUND: To extend investigation beyond global cognitive measures prevalent in the literature, this study examined attention and working memory (WM) abilities of survivors of childhood acute lymphoblastic leukemia (ALL), the separate contributions of attention and WM to intelligence quotient (IQ), and their association with neuroimaging changes. METHODS: Ninety-seven children with ALL received risk-directed therapy based on presenting clinical and biological factors. During consolidation therapy, low-risk patients received half the dose of intravenous methotrexate that standard-risk/high-risk patients received, and fewer doses of triple intrathecal therapy. Patients were classified according to end of consolidation magnetic resonance imaging scans (normal or leukoencephalopathy), and continuous measures of white matter structure were computed. As part of the protocol study, children completed cognitive assessment 2 years later (completion of therapy), using Digit Span Forward (DSF) for attention and Digit Span Backward (DSB) for WM. RESULTS: For the total sample and the standard-/high-risk group, Total Digit Span (TDS), DSF, and DSB were impaired relative to norms (P<.05). In the low-risk group, only DSB was impaired (P<.0001). Across groups, a higher percentage of patients performed below the average range (scale score<7) on DSB (66%) compared with the DSF (14%) or TDS (18%). Regression analysis indicated that DSB predicted estimated IQ (P<.05), after accounting for DSF. Leukoencephalopathy was predictive of lower TDS (P<.05). CONCLUSIONS: WM appears to be especially sensitive to treatment-related changes in ALL survivors, detecting difficulties potentially missed by global intelligence measures. These findings may facilitate the identification of vulnerable neural pathways and the development of targeted cognitive interventions.
BACKGROUND: To extend investigation beyond global cognitive measures prevalent in the literature, this study examined attention and working memory (WM) abilities of survivors of childhood acute lymphoblastic leukemia (ALL), the separate contributions of attention and WM to intelligence quotient (IQ), and their association with neuroimaging changes. METHODS: Ninety-seven children with ALL received risk-directed therapy based on presenting clinical and biological factors. During consolidation therapy, low-risk patients received half the dose of intravenous methotrexate that standard-risk/high-risk patients received, and fewer doses of triple intrathecal therapy. Patients were classified according to end of consolidation magnetic resonance imaging scans (normal or leukoencephalopathy), and continuous measures of white matter structure were computed. As part of the protocol study, children completed cognitive assessment 2 years later (completion of therapy), using Digit Span Forward (DSF) for attention and Digit Span Backward (DSB) for WM. RESULTS: For the total sample and the standard-/high-risk group, Total Digit Span (TDS), DSF, and DSB were impaired relative to norms (P<.05). In the low-risk group, only DSB was impaired (P<.0001). Across groups, a higher percentage of patients performed below the average range (scale score<7) on DSB (66%) compared with the DSF (14%) or TDS (18%). Regression analysis indicated that DSB predicted estimated IQ (P<.05), after accounting for DSF. Leukoencephalopathy was predictive of lower TDS (P<.05). CONCLUSIONS: WM appears to be especially sensitive to treatment-related changes in ALL survivors, detecting difficulties potentially missed by global intelligence measures. These findings may facilitate the identification of vulnerable neural pathways and the development of targeted cognitive interventions.
Authors: Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Chin-Shang Li; Ching-Hon Pui Journal: AJNR Am J Neuroradiol Date: 2005-10 Impact factor: 3.825
Authors: Wilburn E Reddick; John O Glass; Kathleen J Helton; James W Langston; Xiaoping Xiong; Shengjie Wu; Ching-Hon Pui Journal: AJNR Am J Neuroradiol Date: 2005-05 Impact factor: 3.825
Authors: Heather M Conklin; Raja B Khan; Wilburn E Reddick; Susan Helton; Ronald Brown; Scott C Howard; Melanie Bonner; Robbin Christensen; Shengjie Wu; Xiaoping Xiong; Raymond K Mulhern Journal: J Pediatr Psychol Date: 2007-06-14
Authors: Robert W Butler; Donna R Copeland; Diane L Fairclough; Raymond K Mulhern; Ernest R Katz; Anne E Kazak; Robert B Noll; Sunita K Patel; Olle Jane Z Sahler Journal: J Consult Clin Psychol Date: 2008-06
Authors: Kathleen C Insel; Marilyn J Hockenberry; Lynette L Harris; Kari M Koerner; Zhenqiang Lu; Kristin B Adkins; Olga A Taylor; Patricia M Gundy; Ida M Moore Journal: Oncol Nurs Forum Date: 2017-07-01 Impact factor: 2.172
Authors: Peter D Cole; Veena Vijayanathan; Nafeeza F Ali; Mark E Wagshul; Eric J Tanenbaum; Jeremy Price; Vidhi Dalal; Maria E Gulinello Journal: Clin Cancer Res Date: 2013-07-05 Impact factor: 12.531
Authors: Lauren E Cox; Jason M Ashford; Kellie N Clark; Karen Martin-Elbahesh; Kristina K Hardy; Thomas E Merchant; Robert J Ogg; Sima Jeha; Victoria W Willard; Lu Huang; Hui Zhang; Heather M Conklin Journal: Neurooncol Pract Date: 2015-03-13
Authors: Deborah P Waber; Jennifer Turek Queally; Lori Catania; Philippe Robaey; Ivonne Romero; Heather Adams; Cheryl Alyman; Christine Jandet-Brunet; Stephen E Sallan; Lewis B Silverman Journal: Pediatr Blood Cancer Date: 2011-06-30 Impact factor: 3.167
Authors: Amanda L Winter; Heather M Conklin; Vida L Tyc; Heather Stancel; Pamela S Hinds; Melissa M Hudson; Lisa S Kahalley Journal: J Clin Exp Neuropsychol Date: 2014-08-15 Impact factor: 2.475
Authors: Wilburn E Reddick; Delaram J Taghipour; John O Glass; Jason Ashford; Xiaoping Xiong; Shengjie Wu; Melanie Bonner; Raja B Khan; Heather M Conklin Journal: Pediatr Blood Cancer Date: 2014-01-25 Impact factor: 3.167
Authors: Lisa S Kahalley; Heather M Conklin; Vida L Tyc; Melissa M Hudson; Stephanie J Wilson; Shengjie Wu; Xiaoping Xiong; Pamela S Hinds Journal: Psychooncology Date: 2013-02-28 Impact factor: 3.894